181 related articles for article (PubMed ID: 27183614)
1. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
Hillman Y; Mazkereth N; Farberov L; Shomron N; Fishelson Z
J Immunol; 2016 Jun; 196(12):5156-65. PubMed ID: 27183614
[TBL] [Abstract][Full Text] [Related]
2. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
Saar Ray M; Moskovich O; Iosefson O; Fishelson Z
J Biol Chem; 2014 May; 289(21):15014-22. PubMed ID: 24719326
[TBL] [Abstract][Full Text] [Related]
3. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.
Mazkereth N; Rocca F; Schubert JR; Geisler C; Hillman Y; Egner A; Fishelson Z
Immunobiology; 2016 Dec; 221(12):1395-1406. PubMed ID: 27475989
[TBL] [Abstract][Full Text] [Related]
4. miR-132-3p regulates antibody-mediated complement-dependent cytotoxicity in colon cancer cells by directly targeting CD55.
Fan Y; Liao J; Wang Y; Wang Z; Zheng H; Wang Y
Clin Exp Immunol; 2023 Mar; 211(1):57-67. PubMed ID: 36571232
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
6. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
Rozenberg P; Ziporen L; Gancz D; Saar-Ray M; Fishelson Z
Cell Death Dis; 2018 Feb; 9(2):150. PubMed ID: 29396434
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy.
Bellone S; Roque D; Cocco E; Gasparrini S; Bortolomai I; Buza N; Abu-Khalaf M; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Br J Cancer; 2012 Apr; 106(9):1543-50. PubMed ID: 22531721
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs Affect Complement Regulator Expression and Mitochondrial Activity to Modulate Cell Resistance to Complement-Dependent Cytotoxicity.
Hillman Y; Mardamshina M; Pasmanik-Chor M; Ziporen L; Geiger T; Shomron N; Fishelson Z
Cancer Immunol Res; 2019 Dec; 7(12):1970-1983. PubMed ID: 31537542
[TBL] [Abstract][Full Text] [Related]
9. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
Pilzer D; Fishelson Z
Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus X protein activates CD59 involving DNA binding and let-7i in protection of hepatoma and hepatic cells from complement attack.
Shan C; Zhang S; Cui W; You X; Kong G; Du Y; Qiu L; Ye L; Zhang X
Carcinogenesis; 2011 Aug; 32(8):1190-7. PubMed ID: 21665888
[TBL] [Abstract][Full Text] [Related]
11. Shear stress-mediated changes in the expression of complement regulatory protein CD59 on human endothelial progenitor cells by ECM-integrinα
Cui X; Zhang X; Bu H; Liu N; Li H; Guan X; Yan H; Wang Y; Zhang H; Ding Y; Cheng M
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):416-421. PubMed ID: 28943429
[TBL] [Abstract][Full Text] [Related]
12. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab.
Mamidi S; Cinci M; Hasmann M; Fehring V; Kirschfink M
Mol Oncol; 2013 Jun; 7(3):580-94. PubMed ID: 23474221
[TBL] [Abstract][Full Text] [Related]
13. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.
Spiller OB; Criado-García O; Rodríguez De Córdoba S; Morgan BP
Clin Exp Immunol; 2000 Aug; 121(2):234-41. PubMed ID: 10931136
[TBL] [Abstract][Full Text] [Related]
14. Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
Loeff FC; van Egmond HME; Nijmeijer BA; Falkenburg JHF; Halkes CJ; Jedema I
Leuk Lymphoma; 2017 Sep; 58(9):1-14. PubMed ID: 28140725
[TBL] [Abstract][Full Text] [Related]
15. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.
Jurianz K; Ziegler S; Donin N; Reiter Y; Fishelson Z; Kirschfink M
Int J Cancer; 2001 Sep; 93(6):848-54. PubMed ID: 11519047
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.
Zell S; Geis N; Rutz R; Schultz S; Giese T; Kirschfink M
Clin Exp Immunol; 2007 Dec; 150(3):576-84. PubMed ID: 17903221
[TBL] [Abstract][Full Text] [Related]
17. miRNA-520b and miR-520e sensitize breast cancer cells to complement attack via directly targeting 3'UTR of CD46.
Cui W; Zhang Y; Hu N; Shan C; Zhang S; Zhang W; Zhang X; Ye L
Cancer Biol Ther; 2010 Aug; 10(3):232-41. PubMed ID: 20574151
[TBL] [Abstract][Full Text] [Related]
18. Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.
Fishelson Z; Kirschfink M
Front Immunol; 2019; 10():752. PubMed ID: 31024572
[TBL] [Abstract][Full Text] [Related]
19. A Regulatory Loop Involving miR-200c and NF-κB Modulates Mortalin Expression and Increases Cisplatin Sensitivity in an Ovarian Cancer Cell Line Model.
Huang X; Yan Y; Gui A; Zhu S; Qiu S; Chen F; Liu W; Zuo J; Yang L
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499626
[TBL] [Abstract][Full Text] [Related]
20. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
